Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23199759 | 0.90 | JAK2 (0.33) | ALDH1A1JAK2BTKLPLLIPG | |
| SCHEMBL24109664 | 0.88 | CYP3A4 (0.41) | ALDH1A1JAK2BTKCYP3A4TSHR | |
| SCHEMBL20540203 | 0.86 | LPL (0.39) | JAK2BTKLPLLIPG | |
| SCHEMBL1494643 | 0.83 | LPL (0.37) | ALDH1A1JAK2BTKCYP3A4TSHR | |
| SCHEMBL29503402 | 0.81 | CYP3A4 (0.46) | ALDH1A1JAK2BTKCYP3A4TSHR | |
| SCHEMBL106726 | 0.81 | CYP3A4 (0.46) | ALDH1A1JAK2BTKCYP3A4TSHR | |
| SCHEMBL23202718 | 0.81 | KDM1A (0.31) | ALDH1A1 | |
| SCHEMBL29993417 | 0.79 | JAK2 (0.39) | ALDH1A1JAK2BTKHPGDSMN1; SMN2 | |
| SCHEMBL20540300 | 0.78 | JAK2 (0.41) | JAK2BTKLPLLIPG | |
| SCHEMBL29724522 | 0.78 | JAK2 (0.41) | JAK2BTKLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4045036-B1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4045037-B1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12497383-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250346598-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12371433-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | AMGEN INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240132495-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866429-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4045036-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045037-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-114585359-A | Heteroaryl benzidines for the treatment of PD-L1 diseases | 凯莫森特里克斯股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021076688-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076691-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497383-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885 |
| US-20230322731-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885 |
| US-12371433-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885 |
| US-11713307-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885 |
| US-20250346598-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885 |
| US-20210130347-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885 |
| US-11866429-B2 | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | ALDH1A1 332/4885JAK2 110/4885BTK 1064/4885 |
| US-20210130325-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ALDH1A1 463/4885JAK2 165/4885BTK 1415/4885 |
| US-20240132495-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CD274, PDCD1LG2, PDCD1 | ALDH1A1 378/4885JAK2 99/4885BTK 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.